Rituximab and Intravenous Immunoglobulins for Relapsing Postinfectious Opsoclonus-Myoclonus Syndrome
Authors:
- Wilhelmina G. LeenWLWilhelmina G. Leen
- Corry M. WeemaesCWCorry M. Weemaes
- Marcel M. VerbeekMVMarcel M. Verbeek
- Michèl A. WillemsenMWMichèl A. Willemsen
- Jan J. RotteveelJRJan J. Rotteveel
- 1 September 2008
- journal article
- case report
- Published by Elsevier in Pediatric Neurology
- Vol. 39 (3) , 213-217
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Rituximab for treatment of opsoclonus‐myoclonus syndrome in neuroblastomaPediatric Blood & Cancer, 2008
- An update on opsoclonusCurrent Opinion in Neurology, 2007
- FcγRIII-Dependent Inhibition of Interferon-γ Responses Mediates Suppressive Effects of Intravenous Immune GlobulinImmunity, 2007
- IVIG Therapy: Interfering with Interferon-γImmunity, 2007
- Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunitySpringer Seminars in Immunopathology, 2006
- Rituximab (anti-CD20) Adjunctive Therapy for Opsoclonus-Myoclonus SyndromeJournal of Pediatric Hematology/Oncology, 2006
- B lineage cells in the inflammatory central nervous system environment: Migration, maintenance, local antibody production, and therapeutic modulationAnnals of Neurology, 2006
- Response to rituximab in a child with neuroblastoma and opsoclonus‐myoclonusPediatric Blood & Cancer, 2006
- Immunologic and Clinical Responses to Rituximab in a Child With Opsoclonus-Myoclonus SyndromePediatrics, 2005
- CSF B‐cell expansion in opsoclonus‐myoclonus syndrome: A biomarker of disease activityMovement Disorders, 2004